Exelixis: Positive Results from Phase 3 for Cabozantinib in Neuroendocrine Tumors

 CABINET trial will be unblinded and stopped early due to a dramatic improvement in efficacy per a unanimous recommendation by The Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board –

– Based on positive results, findings will be discussed with the U.S. Food and Drug Administration –

https://finance.yahoo.com/news/exelixis-announces-positive-results-phase-120000195.html